Canadian Mass Spectrometry Veteran, Paul Taylor, Joins Rapid Novor Inc.

Share Article

Canadian Mass Spectrometry Veteran, Paul Taylor, Joins Rapid Novor Inc.

Rapid Novor Inc., the world's leader in antibody protein sequencing using mass spectrometry, today announces that the Canadian mass spectrometry veteran, Mr. Paul Taylor has joined the team as the Core Facility Manager.

Prior to joining Rapid Novor, Mr. Taylor has been the Manager and Senior Proteomics Specialist at SPARC BioCentre, The Hospital for Sick Children in Toronto, for the past ten years. He was also formerly a Principle Scientist at MDS-Proteomics, and the Director of Laboratory Operations at Protana Analytical Services. In the past 20 years, he has been responsible for the planning and set up of the mass spectrometry facilities for multiple centres in Canada. He has published in leading peer-reviewed journals such as International Journal of Cancer, Cell, and Nature.

"We are thrilled to have such an accomplished mass spectrometry veteran joining our team", says Mingjie Xie, co-founder and CEO. "We are at the stage of scaling up our REmAb™ antibody protein sequencing service. Mr. Taylor's experiences and expertise will ensure that our mass spectrometry lab is running smoothly at high throughput to meet the growing customer's needs."

"Mr. Taylor has been a long time adviser to our company", says Dr. Bin Ma, co-founder and Chief Scientist. "Now with his joining in full-time and the several key hires in the past year, we have built a dream team in proteomics. I have great confidence in the team in fulfilling our mission: to advance life science for better human health with next generation protein sequencing."

About Rapid Novor Inc.

Rapid Novor Inc. is the world's leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence antibody proteins without needing to access the producing cell line. As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company's REmAb™ antibody protein sequencing service has allowed for the accurate sequencing of any given antibody proteins on a routine basis. The company's WILD™ service is the first commercially available service that can accurately distinguish the isomeric Isoleucine and Leucine using mass spectrometry. For more information, visit http://www.rapidnovor.com. Follow the company on Twitter @rapidnovor.

Media Contact: Mingjie Xie, Rapid Novor Inc, +1 (519) 593-2260, mxie@rapidnovor.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 

SOURCE Rapid Novor Inc.
                    

Share article on social media or email:

View article via:

Pdf Print